Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial

By sjmartinez • November 14, 2024

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Ansari W, Harrington MA, Simón-Campos A, Chew KW, Pypstra R, Rusnak JM. Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial. Clin Infect Dis. 2024 Nov 11:ciae551. doi: 10.1093/cid/ciae551. Epub ahead of print. PMID: 39523543.

Tags: COVID-19 drug therapy, EPIC-HR, Infectious Diseases, nirmatrelvir, Publications, ritonavir, Symptoms

Leveraging near-real-time patient and population data to incorporate fluctuating risk of severe COVID-19: development and prospective validation of a personalised risk prediction tool

Swinnerton K, Fillmore NR, Vo A, La J, Elbers D, Brophy M, Do NV, Monach PA, Branch-Elliman W. Leveraging near-real-time patient and population data to[...]

Variability of antimicrobial susceptibility of commensal Neisseria species supports its use as a marker of excessive antimicrobial consumption – reflections from the results of a four-country study

Kanesaka I, Foschi C, Marangoni A, Adamson PC, Klausner J, Dong HV, Vanbaelen T, De Baetselier I, de Block T, Manoharan-Basil SS, Kenyon C. Variability[...]

Atkinson TM, Mazumdar M, Van Hyfte G, Lee JY, Li Y, Lynch KA, Webb A, Holland SM, Lubetkin EI, Goldstone S, Einstein MH, Stier EA,[...]